<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30552033</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0070</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>93</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Diagnostic microbiology and infectious disease</Title>
          <ISOAbbreviation>Diagn Microbiol Infect Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In vitro activity of EDTA and TOL-463 against Neisseria gonorrhoeae.</ArticleTitle>
        <Pagination>
          <StartPage>369</StartPage>
          <EndPage>371</EndPage>
          <MedlinePgn>369-371</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diagmicrobio.2018.10.021</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0732-8893(18)30603-5</ELocationID>
        <Abstract>
          <AbstractText>Neisseria gonorrhoeae quickly develops drug resistance. Time-kill curves revealed that EDTA and TOL-463 inhibit growth similar to penicillin, ciprofloxacin, and azithromycin. Furthermore, synergistic and additive antimicrobial interactions occurred when EDTA and TOL-463 were combined with penicillin or azithromycin, respectively, suggesting that further investigations into these unconventional antimicrobials may be advantageous.</AbstractText>
          <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nash</LastName>
            <ForeName>Evelyn E</ForeName>
            <Initials>EE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Sexually Transmitted Disease Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA. Electronic address: lmq5@cdc.gov.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Henning</LastName>
            <ForeName>Tara C</ForeName>
            <Initials>TC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Sexually Transmitted Disease Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pham</LastName>
            <ForeName>Cau D</ForeName>
            <Initials>CD</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Sexually Transmitted Disease Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pettus</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Sexually Transmitted Disease Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharpe</LastName>
            <ForeName>Samera</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Sexually Transmitted Disease Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kersh</LastName>
            <ForeName>Ellen N</ForeName>
            <Initials>EN</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Sexually Transmitted Disease Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CC999999</GrantID>
            <Agency>Intramural CDC HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Diagn Microbiol Infect Dis</MedlineTA>
        <NlmUniqueID>8305899</NlmUniqueID>
        <ISSNLinking>0732-8893</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001888">Boric Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9G34HU7RV0</RegistryNumber>
          <NameOfSubstance UI="D004492">Edetic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R57ZHV85D4</RegistryNumber>
          <NameOfSubstance UI="C032688">boric acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001888" MajorTopicYN="N">Boric Acids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004492" MajorTopicYN="N">Edetic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009344" MajorTopicYN="N">Neisseria gonorrhoeae</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antimicrobial resistance</Keyword>
        <Keyword MajorTopicYN="N">Boric acid</Keyword>
        <Keyword MajorTopicYN="N">Broth microdilution</Keyword>
        <Keyword MajorTopicYN="N">EDTA</Keyword>
        <Keyword MajorTopicYN="N">Neisseria gonorrhoeae</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of interest. The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30552033</ArticleId>
        <ArticleId IdType="mid">NIHMS1028006</ArticleId>
        <ArticleId IdType="pmc">PMC6519449</ArticleId>
        <ArticleId IdType="doi">10.1016/j.diagmicrobio.2018.10.021</ArticleId>
        <ArticleId IdType="pii">S0732-8893(18)30603-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Arnold J, Morgan B. Management of lead encephalopathy with DMSA after exposure to lead-contaminated moonshine.
J Med Toxicol
2015;11(4):464–7. 10.1007/s13181-015-0493-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13181-015-0493-9</ArticleId>
            <ArticleId IdType="pmc">PMC4675610</ArticleId>
            <ArticleId IdType="pubmed">26245877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee DD, Burkard L, Panepinto JC. Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B.
PLoS One
2014;9(1), e87246
10.1371/journal.pone.0087246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0087246</ArticleId>
            <ArticleId IdType="pmc">PMC3907572</ArticleId>
            <ArticleId IdType="pubmed">24498052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley LM, McEwan NA, Nuttall T. Tris-EDTA significantly enhances antibiotic efficacy against multidrug-resistant Pseudomonas aeruginosa in vitro.
Vet Dermatol
2013; 24(5):519–e122. 10.1111/vde.12071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/vde.12071</ArticleId>
            <ArticleId IdType="pubmed">24025021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control &amp; Prevention (CDC).
Neisseria Gonorrhoeae reference strains for antimicrobial susceptiblity testing.
https://www.cdc.gov/std/gonorrhea/arg/b88-feb-2005.pdf, 2005.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control &amp; Prevention (CDC).
Sexually transmitted disease surveillance 2017
https://www.cdc.gov/std/stats17/2017-STD-Surveillance-Report_CDC-clearance-9.10.18.pdf, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical and Laboratory Standards Institute (CLSI).
Performance standards for antimicrobial susceptiblity testing, CLSI document M100-S27
27th ed. Wayne, PA: CLSI; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>De Seta F, Schmidt M, Vu B, Essmann M, Larsen B. Antifungal mechanisms supporting boric acid therapy of Candida vaginitis.
J Antimicrob Chemother
2009;63(2): 325–36. 10.1093/jac/dkn486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkn486</ArticleId>
            <ArticleId IdType="pubmed">19059942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al.
Failure of dual antimicrobial therapy in treatment of gonorrhea.
N Engl J Med
2016;374(25):2504–6. 10.1056/NEJMc1512757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1512757</ArticleId>
            <ArticleId IdType="pubmed">27332921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finnegan S, Percival SL. EDTA: an antimicrobial and antibiofilm agent for use in wound care.
Adv Wound Care
2015;4(7):415–21. 10.1089/wound.2014.0577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/wound.2014.0577</ArticleId>
            <ArticleId IdType="pmc">PMC4486448</ArticleId>
            <ArticleId IdType="pubmed">26155384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foerster S, Golparian D, Jacobsson S, Hathaway LJ, Low N, Shafer WM, et al.
Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae.
Front Microbiol
2015;6:1377
10.3389/fmicb.2015.01377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2015.01377</ArticleId>
            <ArticleId IdType="pmc">PMC4674575</ArticleId>
            <ArticleId IdType="pubmed">26696986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamoud R, Reichling J, Wink M. Synergistic antimicrobial activity of combinations of sanguinarine and EDTA with vancomycin against multidrug resistant bacteria.
Drug Metab Lett
2014;8(2):119–28. 10.2174/187231280802150212100742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/187231280802150212100742</ArticleId>
            <ArticleId IdType="pubmed">25692301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson SR, Grad Y, Ganakammal SR, Burroughs M, France M, Lipsitch M, et al.
In vitro selection of Neisseria gonorrhoeae mutants with elevated MIC values and increased resistance to cephalosporins.
Antimicrob Agents Chemother
2014;58(11):6986–9. 10.1128/AAC.03082-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.03082-14</ArticleId>
            <ArticleId IdType="pmc">PMC4249396</ArticleId>
            <ArticleId IdType="pubmed">25199775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, et al.
Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial.
Clin Infect Dis
2018. 
10.1093/cid/ciy554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciy554</ArticleId>
            <ArticleId IdType="pmc">PMC6376090</ArticleId>
            <ArticleId IdType="pubmed">30184181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meletiadis J, Pounaras S, Roilides E, Walsh TJ. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-–in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.
Antimicrob Agents Chemother
2010;54(2):602–9. 10.1128/AAC.00999-09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00999-09</ArticleId>
            <ArticleId IdType="pmc">PMC2812160</ArticleId>
            <ArticleId IdType="pubmed">19995928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa M, Nakajima Y, Kubota R, Endo Y. Two cases of acute lead poisoning due to occupational exposure to lead.
Clin Toxicol (Phila)
2008;46(4):332–5. 10.1080/15563650701816448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15563650701816448</ArticleId>
            <ArticleId IdType="pubmed">18363133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papp JR, Abrams AJ, Nash E, Katz AR, Kirkcaldy RD, O’Connor NP, et al.
Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii, USA.
Emerg Infect Dis
2017;23(5):830–2. 10.3201/eid2305.170088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid2305.170088</ArticleId>
            <ArticleId IdType="pmc">PMC5403062</ArticleId>
            <ArticleId IdType="pubmed">28418303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares GM, Figueiredo LC, Faveri M, Cortelli SC, Duarte PM, Feres M. Mechanisms of action of systemic antibiotics used in periodontal treatment and mechanisms of bacterial resistance to these drugs.
J Appl Oral Sci
2012;20(3):295–309. 10.1590/S1678-77572012000300002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S1678-77572012000300002</ArticleId>
            <ArticleId IdType="pmc">PMC3881775</ArticleId>
            <ArticleId IdType="pubmed">22858695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat J, et al.
Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pandrug-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother
2010;54 (11):4678–83. 10.1128/AAC.00497-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00497-10</ArticleId>
            <ArticleId IdType="pmc">PMC2976112</ArticleId>
            <ArticleId IdType="pubmed">20713678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.
Future Microbiol
2012;7(12):1401–22. 10.2217/fmb.12.117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fmb.12.117</ArticleId>
            <ArticleId IdType="pmc">PMC3629839</ArticleId>
            <ArticleId IdType="pubmed">23231489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wade JJ, Graver MA. A fully defined, clear and protein-free liquid medium permitting dense growth of Neisseria gonorrhoeae from very low inocula.
FEMS Microbiol Lett
2007;273(1):35–7. 10.1111/j.1574-6968.2007.00776.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1574-6968.2007.00776.x</ArticleId>
            <ArticleId IdType="pubmed">17559396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015.
MMWR Recomm Rep
2015;64(RR-03):1–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5885289</ArticleId>
            <ArticleId IdType="pubmed">26042815</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
